Mersana Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	36.86	26.58	0.04	0.83	42.12	10.59	17.55	25.17	10.36
Revenue Growth (YoY)	38.65%	61716.28%	-94.81%	-98.03%	297.61%	-39.62%	-30.30%	142.99%	-
Gross Profit	36.86	26.58	0.04	0.83	42.12	10.59	17.55	25.17	10.36
Selling, General & Admin	59.54	56.96	36.89	21.9	17.28	16.33	10.46	6.98	5.35
Research & Development	148.27	173.39	132.01	67.04	55.04	59.92	46.7	32.01	21.35
Other Operating Expenses	8.71	0	0	0	0	0	0	0	0
Operating Expenses	216.53	230.35	168.9	88.94	72.32	76.25	57.16	38.99	26.7
Operating Income	-179.67	-203.77	-168.86	-88.11	-30.2	-65.66	-39.62	-13.82	-16.34
Interest Expense / Income	4.07	3.33	1.27	0.36	0.23	0	0	0	0
Other Expense / Income	-12.07	-2.88	-0.07	-0.42	-2.23	-1.4	-0.91	-0.12	0.09
Pretax Income	-171.67	-204.21	-170.06	-88.05	-28.21	-64.26	-38.71	-13.7	-16.43
Net Income	-171.67	-204.21	-170.06	-88.05	-28.21	-64.26	-38.71	-13.7	-16.43
Shares Outstanding (Basic)	116	94	71	61	43	23	12	1	1
Shares Outstanding (Diluted)	116	94	71	61	43	23	12	1	1
Shares Change	23.98%	32.69%	14.79%	41.37%	88.83%	91.57%	849.09%	3.54%	-
EPS (Basic)	-1.48	-2.18	-2.41	-1.43	-0.65	-2.79	-3.22	-10.82	-13.43
EPS (Diluted)	-1.48	-2.18	-2.41	-1.43	-0.65	-2.79	-3.22	-10.82	-13.43
Free Cash Flow	-171.05	-51.56	-140.64	-75.17	-68.35	-56.59	-43.82	30.5	-10.26
Free Cash Flow Per Share	-1.47	-0.55	-1.99	-1.22	-1.57	-2.46	-3.65	24.08	-8.38
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-487.51%	-766.59%	-392693.02%	-10641.30%	-71.69%	-619.74%	-225.80%	-54.91%	-157.75%
Profit Margin	-465.80%	-768.26%	-395488.37%	-10633.45%	-66.97%	-606.54%	-220.62%	-54.43%	-158.59%
Free Cash Flow Margin	-464.12%	-193.97%	-327060.47%	-9078.38%	-162.26%	-534.13%	-249.77%	121.19%	-99.00%
EBITDA	-163.3	-197.18	-166.11	-86.68	-26.73	-63	-37.78	-13.05	-16.13
EBITDA Margin	-443.09%	-741.81%	-386300.00%	-10468.12%	-63.45%	-594.68%	-215.33%	-51.83%	-155.72%
Depreciation & Amortization	4.3	3.7	2.68	1.01	1.25	1.26	0.93	0.66	0.3
EBIT	-167.6	-200.88	-168.79	-87.69	-27.97	-64.26	-38.71	-13.7	-16.43
EBIT Margin	-454.75%	-755.74%	-392541.86%	-10590.10%	-66.41%	-606.54%	-220.62%	-54.43%	-158.59%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).